Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease

@inproceedings{Hajj2015CombinationOA,
  title={Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease},
  author={Rodolphe Hajj and Aude Milet and Damien Toulorge and Nathalie Cholet and Julien Laffaire and Julie Foucquier and Sandra Robelet and R. M. Mitry and Mickael Guedj and Serguei Nabirotchkin and Ilya Chumakov and Daniel Cohen},
  booktitle={Scientific reports},
  year={2015}
}
  • Rodolphe Hajj, Aude Milet, +9 authors Daniel Cohen
  • Published in Scientific reports 2015
  • Medicine
  • Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopaminergic nigrostriatal neurons but which involves the loss of additional neurotransmitter pathways. Mono- or polytherapeutic interventions in PD patients have declining efficacy long-term and no influence on disease progression. The systematic analysis of available genetic and functional data as well as the substantial overlap between Alzheimer's disease (AD) and PD features led us to repurpose… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-9 OF 9 CITATIONS

    Effect of topology and time window on probability distribution underlying baclofen induced Ca2+ response in hippocampal neurons*

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 69 REFERENCES

    Improving L-dopa therapy: the development of enzyme inhibitors.

    • Oscar S. Gershanik
    • Medicine
    • Movement disorders : official journal of the Movement Disorder Society
    • 2015

    the development of enzyme inhibitors

    • Gershanik, O. S. Improving l-dopa therapy
    • Mov. Disord. 30, 103–13
    • 2015